according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. The findings, published in the New ...

Researchers have revolutionized cancer immunotherapy by developing a way to grow T cells in the lab that live longer and ...

Dr. Abdalla Sholi is an oncologist at UPMC Hillman Cancer Center in Williamsport. He tells Newswatch 16 they offer a lot of services to cancer patients, "We offer chemotherapy, immunotherapy ...

The vaccine was developed after decades of research by University of Pittsburgh and UPMC Hillman Cancer Center immunologist Dr. Olivera Finn. At a presentation Thursday at UPMC Magee-Womens ...

A new way to grow T cells in the lab enables them to live longer and better destroy cancer cells in a mouse model of melanoma compared to those grown in traditional growth media. The findings have the ...

Researchers identify glucose usage as one major divergence betweenT cells expanding in vitro versus those expanding in vivo.

Geyer Jr., MD, of the UPMC Hillman Cancer Center in Pittsburgh, and co-authors in the New England Journal of Medicine. "The KATHERINE study was designed to see if we could use neoadjuvant therapy ...

and professor of medicine in the division of malignant hematology and oncology at University of Pittsburgh Hillman Cancer Center, told Healio. “T-DM1 has been the standard of care for patients ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The study was led by Charles E. Geyer Jr, MD, NSABP Foundation and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania. It was published online on ...